Nice little MSN article today20 May 2025 21:52
Solvonis Therapeutics plc has successfully raised approximately Ā£2.0 million through the issuance of new ordinary shares, representing a significant portion of its pre-fundraise share capital. This capital raise, facilitated by joint brokers Allenby Capital Limited and Singer Capital Markets Securities Limited, is expected to enhance Solvonisās financial position and support its strategic initiatives in the mental health therapeutics sector. The new shares will be admitted to trading on the London Stock Exchange, with trading expected to commence on 27 May 2025. The fundraise also includes participation from key company directors, highlighting confidence in the companyās future prospects.